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Receptor Family Signal Transduction
via activation of apical caspases. In most instances,
TNFR1 signaling results in NF-B activation. However,
cell death can be triggered by TNFR1 under conditions
where new protein synthesis is blocked or where NF-
B activation is specifically inhibited prior to TNF stimu-
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and Skin Diseases lation (Varfolomeev and Ashkenazi, 2004). In vivo, when
NF-B activation is blocked, endogenous TNF signalingNational Institutes of Health
Bethesda, Maryland 20892 through TNFR1 can lead to embryonic lethality due to
massive liver cell death during development (Beg and2 Institute of Biochemistry
University of Lausanne Baltimore, 1996).
Unlike TNFR1, Fas is relatively weak at inducing NF-BIL Biomedical Research Center
Chemin des Boveresses 155 B and primarily induces programmed cell death. How-
ever, susceptibility to Fas-mediated apoptosis can beCH-1066 Epalinges
Switzerland regulated independently of receptor expression. Mixing
experiments with Fas-expressing activated CD4 T cells3 Department of Pharmacology, Toxicology,
and Therapeutics have shown that only T cells receiving TCR restimulation
become susceptible to FasL-dependent apoptosis whileUniversity of Kansas Medical Center
Kansas City, Kansas 66160 bystander activated T cells of different antigenic speci-
ficity in the same cultures do not undergo apoptosis
(Combadiere et al., 1998). This “competency to die” sig-
nal can be triggered by weak TCR agonists, is indepen-
dent of CD28 costimulation, and does not appear toSignaling by receptors in the TNF receptor (TNFR) su-
perfamily mediate biological outcomes ranging from require new RNA or protein synthesis.
Recent data has shed new light on how membraneinflammation to apoptosis and other forms of pro-
grammed cell death. How receptor signaling mediates proximal events control fate decisions in signaling by
two members of the TNFR family, TNFR1 and Fas. Here,these divergent responses is just beginning to be un-
derstood. Here, we discuss how receptor submembrane we review how distinct signaling complexes can trigger
alternative fates of cells after TNF receptor triggering.localization and the formation of alternate signaling
complexes can alter the fate of cells stimulated In addition, we discuss how receptor localization in lipid
raft microdomains can alter proximal signaling eventsthrough TNFRs with a death domain, also known as
“death receptors.” by TNF family receptors and ultimately affect cell fate.
These new findings have significant implications for our
understanding of the function of TNF family members
in the immune system.The Tumor Necrosis Factor receptor (TNFR) superfamily
has grown to 32 members and 19 ligands (a down-
loadable table can be accessed at http://www.irp.niams. Secondary Complexes in TNFR Signaling
nih.gov/ImageStore/Test/WORD/AB/IRG/tnfchart.doc). After TNF binding to TNFR1, the adaptor protein TRADD
TNF family receptors orchestrate many aspects of im- is recruited through interactions between the death do-
mune cell function, including lymphoid organ develop- mains in the receptor cytoplasmic tail and the C-terminal
ment, acute inflammation, and lymphocyte costimulation portion of TRADD. It has been shown that FADD and
(Bodmer et al., 2002). Blocking TNF-TNFR1 interactions caspase-8 are required for TNFR1-mediated cell death.
has emerged as a powerful and clinically effective dis- However, direct association of these molecules with en-
ease-modifying therapy for autoimmune conditions dogenous TNFR1 has not been seen. In addition, al-
such as rheumatoid arthritis and inflammatory bowel though many studies have shown that inhibition of NF-
disease, and therapies based on blocking the actions B activity can sensitize cells to die through TNFR1, it
of other members of the TNF family are under devel- was not clear how NF-B activation by TNFR1 could
opment. act quickly enough to inhibit apical caspase activation
through the same receptor.
Divergent Signaling by TNFR Family Members A solution to this paradox has been proposed in the
One of the most fascinating aspects of TNFR biology is recent finding that TNFR1 signaling involves assembly
the diversity of responses triggered through each recep- of two molecularly and spatially distinct signaling com-
tor. The presence of a particular TNFR family member plexes that sequentially activate NF-B and caspases
on the cell surface does not generally predict efficacy (Figure 1) (Micheau and Tschopp, 2003). Within a few
or biological outcome of signaling by that receptor. In- minutes of TNF binding to TNFR1, a signaling complex
stead, signaling by these receptors is dependent on cell- termed “complex I” forms. This complex contains the
type and environmental factors. For example, TNFR1 receptor itself, RIP1, TRAF2, and TRADD. Complex I
can trigger cellular activation via NF-B or apoptosis transduces signals that lead to NF-B activation through
recruitment of the I-B kinase “signalsome” high molec-
ular weight complex (Poyet et al., 2000; Zhang et al., 2000).*Correspondence: rsiegel@nih.gov
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Figure 1. Alternate Complexes and Role of JNK in TNFR1 Signaling
Early after TNF binding, RIP1, TRADD, TRAF2, and cIAP1 are recruited to TNFR1 to form complex I. Complex I transduces signals leading to
NF-B translocation. At later time points, RIP1, TRADD, and TRAF2 dissociate from TNFR1 and recruit FADD and caspase-8 to form complex
II. In the absence of NF-B activity from complex I, complex II can initiate caspase-8 activation and cell death. NF-B inhibits cell death
through upregulation of antiapoptotic genes such as c-FLIP, which directly inhibits caspase activation in complex II or through suppression
of JNK activity, possibly through upregulation of A20. Sustained TNFR1-mediated JNK activation results in the cleavage of Bid to jBid, which
then induces the preferential release of SMAC from the mitochondria. Released SMAC interferes with cIAP1-mediated inhibition of caspase-8.
At late time points (2 hr) after TNFR1 triggering, negative regulators of TNFR1 apoptosis signaling are
the BIR-repeat containing proteins cIAP-1 and cIAP-2possibly after receptor internalization, RIP1, TRAF2, and
TRADD dissociate from the receptor and recruit FADD and the TRAF and RING finger-containing proteins
TRAF1 and TRAF2 (Wang et al., 1998).and caspase-8 into a secondary complex (complex II).
In situations where complex I or other exogenous factors In addition to activating antiapoptotic genes, NF-B
can suppress apoptosis by inhibiting sustained activa-trigger sufficient NF-B signaling, gene expression of
antiapoptotic proteins is induced and the activation of tion of the MAP-kinase family member Jun-Kinase (JNK)
(Tang et al., 2001). Although interfering with JNK activa-apical caspases in complex II is inhibited. However,
when NF-B activity is deficient, these gene products tion can suppress apoptosis, sustained JNK activation
itself is dependent on the mitochondrial permeabilityare not made, and complex II can signal for apoptosis.
Because of the long delay in complex II assembly, there transition, a central feature of apoptosis. Thus it was
not clear whether JNK activation precedes or dependsis time for antiapoptotic proteins to be synthesized and
complete the negative feedback loop. In this way, the on mitochondrial changes in apoptosis. A recent study
proposed a novel mechanism to connect JNK activationability of complex I to activate NF-B early after TNF
binding acts as a checkpoint to control whether complex with mitochondrial events in apoptosis (Deng et al.,
2003). When NF-B was inhibited, TNFR1 signaling in-II can induce apoptosis a few hours later.
Several NF-B target genes have been proposed to duced sustained JNK activation that results in the cas-
pase-8-independent cleavage of Bid to a novel cleavageinhibit TNFR1-induced apoptosis. The gene for the cellu-
lar FLICE-like inhibitory protein (c-FLIP) is upregulated product termed jBid. jBid induced the preferential re-
lease of the proapoptotic factor SMAC/Diablo from theby NF-B and can inhibit caspase-8 activation in the
Fas signaling complex (Irmler et al., 1997; Micheau et mitochondria. SMAC/Diablo may then relieve the inhibi-
tion of cIAP1 on caspase-8 and positively feed back onal., 2001). In TNF-stimulated cells, c-FLIP is recruited to
complex II, where it inhibits caspase activation (Micheau the apoptotic protease cascade (see Figure 1) (Deng et
al., 2003). Although a direct association between cIAP1and Tschopp, 2003). Indeed, MEFs that are deficient for
c-FLIP undergo cell death in response to TNF whereas and caspase-8 has not been demonstrated, it may be
possible that this inhibition is indirect.wt MEFs do not (Yeh et al., 2000). Other candidates for
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Figure 2. Examples of How Lipid Rafts Can Modify Early Events in TNFR Family Signaling
(A) In activated CD4 T cells, Fas is excluded from lipid rafts. Outside of lipid rafts, Fas is likely to be monomeric. After engagement by FasL,
although FADD and caspase-8 are recruited to Fas, they do not signal efficiently for death. Upon TCR restimulation, Fas translocates into
lipid rafts where it tends to preassociate. Within lipid rafts, upon FasL binding, FADD and caspase-8 are recruited to Fas where caspase-8
can autoactivate and trigger cell death.
(B) Upon TNF binding, TNFR1 translocates into lipid rafts wherein complex I formation takes place and results in the activation of NF-B.
Through mechanisms described in Figure 1, NF-B can inhibit caspase activation within complex II. When cholesterol is depleted, lipid raft
structure is disrupted and complex I forms outside of lipid rafts and cannot signal efficiently for NF-B and therefore cannot inhibit death
induced by complex II. The thickness of the arrows indicates relative efficiency of each signaling pathway.
A number of NF-B target genes have been proposed immune cells, and understanding how alternative TNFR1
signaling complexes are regulated in the immune sys-to suppress the sustained JNK activity that is associated
with apoptosis. GADD45 and XIAP were isolated in tem is an important goal. TNF can act as a costimulator
of T cell activation through TNFR2, a non-death domaingenetic screens for NF-B target genes that can protect
from cell death and do perform this function when over- containing TNFR, but in activated T cells TNF can con-
tribute to TCR-induced cell death in a TNFR2-dependentexpressed in cell lines (De Smaele et al., 2001; Tang et
al., 2001). However, primary cells from GADD45- and manner (Zheng et al., 1995). TNFR2 has been shown to
sensitize T cells to die via induced ubiquitin-dependentXIAP-deficient mice are not hypersensitive to TNF-induced
cytotoxicity, suggesting that there may be functional degradation of TRAF2 (Chan and Lenardo, 2000; Li et
al., 2002). In light of the findings discussed here, TRAF2redundancy in these pathways (Amanullah et al., 2003;
Harlin et al., 2001). Targeted disruption of XIAP did sensi- downregulation may promote cell death by enhancing
the activity of complex II. Interestingly, a number oftize a human colon cancer cell line to cell death induced
by the TNF-related apoptosis-inducing ligand (TRAIL), bacterial effector proteins, such as Yersinia YopJ, ap-
pear to target NF-B signaling and sensitize cells toindicating that the role of XIAP may be different in trans-
formed cells (Cummins et al., 2004). Another NF-B tar- apoptosis, whereas activation of NF-B by intracellular
pathogens can protect infected cells from death recep-get gene, the cytoplasmic zinc finger protein A20
(TNFAIP3), dramatically affects cell fate in response to tor-induced apoptosis. Anti-inflammatory therapeutic
agents that can inhibit NF-B, such as glucocorticoids,TNF. A20-deficient thymocytes and MEFs undergo in-
creased apoptosis in response to TNF despite sustained sulfasalazine, salicylates, or thalidomide derivatives,
may also sensitize cells to TNF-induced apoptosis.NF-B and JNK activation. A20-deficient mice exhibit
lymphocyte-independent systemic inflammation and
have increased liver cell death (Lee et al., 2000). Thus Lipid Rafts as Dynamic Modulators of TNFR
Family SignalingA20 is a good candidate for a TNF-induced negative
regulator of JNK. Liquid-ordered microdomains enriched in sphingolipids
and cholesterol constitute a distinct biophysical plasmaMany of these observations were initially made in non-
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membrane compartment. They have been termed lipid distributed within lipid rafts (Muppidi and Siegel, 2004).
rafts based on their ability to float in a discontinuous Other groups have also recently found similar alterations
density gradient after lysis in nonionic detergents in the lipid raft localization of Fas between type I and
(Munro, 2003; Simons and Toomre, 2000). It has been type II cell lines (Eramo et al., 2004).
proposed that lipid rafts serve as signaling platforms Modulation of lipid raft localization of Fas may be
for BCR, TCR, and Fc antigen receptors, bringing the relevant to the “competency signal” for apoptosis deliv-
receptors into proximity with activating kinases that are ered by the TCR in activated CD4 T cells. Like type II
constitutive residents of lipid rafts (Dykstra et al., 2003). cell lines, human CD4T cell blasts are relatively insensi-
Although membrane-anchored kinases do not appear tive to bivalent anti-Fas antibodies or endogenously pro-
to participate in TNFR family signaling, the local environ- duced FasL. Fas in these cells does not partition into
ment of the membrane may influence the efficiency of lipid rafts. However, TCR restimulation induces a ligand-
signaling and composition of receptor signaling com- independent redistribution of Fas into lipid rafts that
plexes. renders CD4 T cells sensitive to these stimuli. Choles-
Recent findings have delineated distinct roles for lipid terol depletion inhibits this TCR-mediated sensitization
rafts in Fas and TNFR1 signaling (Figure 2). After TNF to Fas-induced apoptosis (Muppidi and Siegel, 2004).
binding in the human fibrosarcoma cell line HT1080, The concept that Fas association with lipid rafts varies
TNFR1 translocates to lipid rafts within 2 min, where between cell types may resolve some of the apparent
RIP1, TRADD, and TRAF2 are recruited (Legler et al., discrepancies in the literature regarding the role lipid
2003). TRAF2, the adaptor molecule that links TNFR1 to rafts in Fas signaling. For example, in thymocytes, which
NF-B activation, has been reported to be constitutively are type I cells, Fas localizes to lipid rafts and cholesterol
present in lipid rafts. When lipid rafts are disrupted by
depletion, which disrupts lipid raft structure and can
cholesterol depletion, phosphorylation of IB in re-
inhibit Fas-induced cell death (Hueber et al., 2002). How-
sponse to TNF is inhibited and apoptosis is induced
ever, in the human fibrosarcoma cell line HT1080, which(Legler et al., 2003). These findings may be cell-type
is likely type II, Fas is excluded from lipid rafts, anddependent. In the myeloid cell line U937, TNFR1-
cholesterol depletion does not inhibit cell death inducedinduced apoptosis has been reported to depend on lipid
by crosslinked anti-Fas or FasL stimuli (Legler et al.,raft integrity, while in primary mouse macrophages, lipid
2003).rafts appear to allow TNFR1 to signal for ERK activation,
It may seem paradoxical that disruption of lipid raftsbut not NF-B (Doan et al., 2004; Ko et al., 1999).
can desensitize cells to Fas-induced cell death and yetFor Fas, where a death signaling complex is recruited
sensitize cells to TNFR1-induced cell death unless onedirectly to the cytoplasmic tail of the receptor, the re-
considers how signals are transduced through theseported localization of Fas in lipid rafts and a requirement
receptors. TNFR1 signals for NF-B via the receptor-for lipid raft integrity in Fas-mediated apoptosis has
associated complex I and cell death via complex II,varied widely (Algeciras-Schimnich et al., 2002; Eramo
which is not receptor associated (Figure 1). However,et al., 2004; Hueber et al., 2002; Muppidi and Siegel,
Fas can trigger cell death via the receptor-associated2004). Some of these differences may be explained by
DISC. Thus the divergent outcomes of lipid raft disrup-variation in the potency of Fas ligands and anti-Fas
tion may reflect the function of lipid rafts to enhanceantibodies used in these studies. More importantly,
the mechanism of Fas signaling itself appears to vary the efficiency of signaling in the receptor-associated
between cell types. In cell lines termed “type I,” the primary signaling complex (Figure 2). Indeed, lipid raft
death-inducing signal complex (DISC), consisting of disruption blocks the ubiquitination of the adaptor pro-
Fas, FADD, and caspase-8, is easily detected, and Fas- teins RIP1 and TRADD in the TNFR-1 signaling complex
induced cell death cannot be blocked by overexpression and prevents NF-B induction by complex I (Legler et
of anti-apoptotic Bcl-2 family members. In type II cell al., 2003).
lines the DISC is less easily detected, and overexpres-
sion of antiapoptotic Bcl-2 family members blocks Fas-
induced cell death (Scaffidi et al., 1998). Future Challenges
We have recently correlated the mode and efficiency The studies discussed here show that far from being
of Fas signaling with the submembrane localization of “hard-wired” to elicit a certain response, TNFR signaling
the receptor. In type I cells, a portion of Fas resides should be seen as a dynamic process that is subject to
constitutively in lipid rafts, while in type II cells, the the influence of other signaling pathways, environmen-
receptor is excluded from lipid rafts during early signal- tal, and genetic factors. Whether findings from Fas and
ing (Muppidi and Siegel, 2004). The presence of Fas in
TNFR1 are applicable to the receptors in the TNFR su-
lipid rafts allows type I cells to undergo apoptosis in
perfamily that do not have a cytoplasmic death domainresponse to weak bivalent anti-Fas stimulation, which
and bind directly to TRAFs is not yet clear. Yet it is likelycannot induce apoptosis in type II cell lines. Disruption
that further studies of the TNFR superfamily will yieldof lipid raft structure by cholesterol depletion reduces
more interesting receptor biology and targets for immu-signaling efficiency in type I cells, but not in type II cells.
notherapy.Lipid rafts may modulate signaling efficiency of Fas by
modulating receptor preassociation, which has been
previously been shown to be important in Fas-mediated Acknowledgments
apoptosis (Siegel et al., 2000). Crosslinking studies
showed that Fas is preassociated in type I, but not type We would like to thank members of the Siegel lab and the reviewers
for helpful discussionsII, cells. In type I cells, preassociated Fas is preferentially
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